Corporate | 13 August 2025 07:37
Medios accelerates growth in the first half of 2025 and significantly increases earnings
|
Medios AG
/ Key word(s): Half Year Report/Half Year Results
Press release Medios accelerates growth in the first half of 2025 and significantly increases earnings
Berlin, August 13, 2025 – The Medios-Group (“Medios“ or “the Company”), a leading provider of Specialty Pharma in Europe, continues its positive operational development in the second quarter of 2025 and confirms its forecast for the full year. Due to dynamic revenue growth of 12.4% in the second quarter of 2025, revenue for the first half of the year increased by 9.3% to €991.7 million. All business segments contributed to this growth. EBITDA pre 1 rose again disproportionately by 48.8% to €46.3 million (H1 2024: €31.1 million). Organic EBITDA pre 1 growth amounted to 12.3%. As a result, the EBITDA pre 1 margin improved significantly to 4.7% (H1 2024: 3.4%). Consolidated net income after income taxes doubled to €12.7 million (H1 2024: €6.4 million). Accordingly, earnings per share reached €0.50 – an increase of 85.2% (H1 2024: €0.27). Matthias Gaertner, CEO of Medios AG: “We accelerated our growth momentum in the second quarter. I am particularly pleased with the organic EBITDA pre growth of 12.3% that significantly exceeded our growth target in the mid-single-digit range. As a result, we have once again succeeded in increasing our overall profitability. This confirms the operational strength of our company and our strategy, which is focused on increasing margins while maintaining growth.” Revenue and earnings growth in all business segments The Pharmaceutical Supply segment achieved revenue growth to €800.1 million in the first half of 2025 (H1 2024: €787.9 million). EBITDA pre 1 for the division increased significantly by 15.4% to €26.4 million (H1 2024: €22.9 million) as a result of the strategic focus on higher-margin products. The Patient-Specific Therapies segment recorded an increase in revenue to €110.2 million in the first half of 2025 (H1 2024: €107.5 million). EBITDA pre 1 for the segment increased by 10.8% to €12.1 million (H1 2024: €10.9 million), driven by a better product mix and a higher gross profit margin. The International Business segment, which comprises the activities of Ceban Pharmaceuticals, included in the scope of consolidation since June 1, 2024, generated revenue of €81.1 million in the first half of 2025 (H1 2024 for June: €11.6 million). The segment contributed €13.8 million to EBITDA pre 1 (H1 2024 for June: €2.7 million). Public share buyback offer successfully completed Medios conducted a public buyback offer from June 18 to July 8, 2025. A total of 1,000,000 no-par value shares were acquired at a price of €12.50. Medios has thus repurchased shares representing approx. 3.92% of the current share capital. Outlook for 2025 confirmed Medios confirms its forecast for the 2025 financial year. The Company expects revenue to increase by around 6% to approx. €2 billion. EBITDA pre 1 is expected to rise disproportionately by approx. 21.5% to around €96 million. This corresponds to a further increase in the EBITDA pre 1 margin to around 4.8%. This expectation is based on the assumption of organic growth in the mid-single-digit percentage range and takes into account the consolidation of the Ceban Group for twelve months.
The half-year financial report of Medios AG as of June 30, 2025, is available for download on the Investor Relations website. Important dates for Medios in the 2025 financial year:
1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options, expenses for M&A activities and, in 2023 and 2024, performance-related payments for the acquisition of compounding volumes. Since 2024, expenses for the implementation of the ERP system have also been included. In addition, one-off special expenses related to the change in the Executive Board were adjusted in 2025. ——————- About Medios AG Medios is a leading provider of specialty pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individual medicine in order to work with pharmacies, specialist practices and pharmaceutical companies. Medios AG is Germany’s first listed specialty pharmaceutical company. The shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard).
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Medios AG Heidestraße 9 | 10557 Berlin T +49 30 232 566 800
Disclaimer This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.
13.08.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language: | English |
| Company: | Medios AG |
| Heidestraße 9 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 232 566 – 800 |
| Fax: | +49 30 232 566 – 801 |
| E-mail: | ir@medios.group |
| Internet: | www.medios.group |
| ISIN: | DE000A1MMCC8 |
| WKN: | A1MMCC |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2183156 |
| End of News | EQS News Service |
|
|
2183156 13.08.2025 CET/CEST